Amicus rises after BioMarin's $4.8 billion buyout deal

Amicus Therapeutics

19/12/2025 13:15

** Shares of Amicus Therapeutics FOLD.O rise 30% to $14.16 premarket

** BioMarin Pharmaceutical BMRN.O to buy FOLD in an all-cash deal worth about $4.8 billion

** BMRN will pay $14.50 per share for FOLD, a premium of 33.1% to the stock's last close

** BMRN gains access to FOLD's treatments for genetic disorders Fabry disease and Pompe disease

** Up to last close, FOLD shares up 15.6% YTD

 (Reporting by Puyaan Singh)

 ((Puyaan.Singh@thomsonreuters.com;))